For research use only. Not for therapeutic Use.
Ladarixin sodium is a dual chemokine receptor (CXCR1 and CXCR2) antagonist, used in research related to inflammation and autoimmune diseases. By blocking these receptors, ladarixin sodium inhibits the activity of interleukin-8 (IL-8), a key mediator of inflammation and neutrophil recruitment. This compound is being investigated for its potential in treating various inflammatory conditions, including type 1 diabetes, where it may help preserve pancreatic beta-cell function. Its ability to modulate immune responses and reduce inflammation makes ladarixin sodium a valuable tool in developing therapies for autoimmune and chronic inflammatory diseases.
| Catalog Number | I007609 |
| CAS Number | 865625-56-5 |
| Synonyms | sodium;methylsulfonyl-[(2R)-2-[4-(trifluoromethylsulfonyloxy)phenyl]propanoyl]azanide |
| Molecular Formula | C11H11F3NNaO6S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H12F3NO6S2.Na/c1-7(10(16)15-22(2,17)18)8-3-5-9(6-4-8)21-23(19,20)11(12,13)14;/h3-7H,1-2H3,(H,15,16);/q;+1/p-1/t7-;/m1./s1 |
| InChIKey | QICAUCDBOAKDNS-OGFXRTJISA-M |
| SMILES | CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)[N-]S(=O)(=O)C.[Na+] |
